fbpx

Call Ahead Care Line:  (281) 783-8162

Become a Healthcare 
Current Clinical Research Studies
lungs

Asthma Study

Must be at least 12 years old to participate in the study. Must have a concern, medical diagnosis or other breathing-related symptoms that indicate the possibility of asthma or breathing disorder.  

nosebleed image

Nosebleed Cessation Study

Must be 18 years of age or older to participate in the nosebleed cessation study. Must frequently experience nosebleeds to be considered.

cough

RSV Study

If you have ever tested positive for RSV, this research study may be for you! Must be 18 years of age or older to participate in the study.

coming-soon

Lung Cancer Screening Study

Monitor our website and social media channels for the enrollment date of our Lung Cancer screening studies! 

The Next Level Experience - Our Misson

Next Level Medical Clinical Research is a part of Next Level Urgent Care Clinics located throughout Houston, Austin, San Antonio, & Beaumont Texas area, thus providing a proliferating patient database, 44 well-established urgent care centers, and a trusted reputation within all of our communities. We’re able to provide a large-scale and highly diversified subject population and in doing so, continuously achieve high volunteer recruitment and retention by focusing on our mission of patient-customer centricity.

Since Next Level’s Clinical Research inception of clinical research in 2020, we have successfully conducted and managed clinical trials ranging in multiple therapeutics areas at our primary Tanglewood-Houston facility. Our urgent care centers are located throughout multiple cities enabling the ability to conduct decentralized and/or hybrid clinical trials when warranted to meet the needs of our customers and subject volunteer participants. Throughout our partnerships, we have exhibited resulted oriented successful outcomes by meeting or exceeding our targeted randomization goals, achieving 98% enrollment goals, 98% subject retention rate, and a 2% screen failure ratio

Next Level Medical Clinical Research comprehends the vast significant undertaking of clinical research. We are committed to providing the highest standard of agility, quality results oriented data, and participant care. With a combined experience of over 20 years in clinical research; our dedicated staff of principal investigators are board certified physicians with all applicable certifications such as GCP. Our clinical coordinators hold certifications in HIPPA, GCP and IATA with advanced degrees in areas of BSN-registered nurse, biology, clinical research, and organizational management. 

Why Participate in Clinical Trials?

Our mission is to conduct safe and effective clinical trials to advance development of new medications. It is healthcare heroes like you who make new treatments possible. By participating in a clinical trial you may benefit from new investigational treatments that are not otherwise available to the public. As a participant in the clinical trial, no health insurance is required. You will receive free medical care from expert physicians and all study-related medical exams, laboratory tests, and procedures are provided at no charge. You will receive care from expert physicians and all study-related medical exams, lab tests, and procedures at no charge to you.

You may receive compensation for your time.

There is no cost associated with the visit or medication.

Conveniently located at our Tanglewood Clinic.

Steps for Participation and FAQs

Screening interview: Information will be taken concerning your age, medical history, medications, and other preliminary questions to make sure you meet the study requirements.

Assessments & Medication: Once you are enrolled in a study, you may have a study-related physical exam, receive the study medications, undergo laboratory tests, and other study procedures. During the course of the study, research team members will meet with you regularly to monitor your progress.

Informed Consent: You will receive materials that fully explain the nature of the study and how you will participate. Our research staff will tell you of any known risks or potential side effects. It is very important that you ask questions and read the consent form carefully. Please ask any questions you might have to fully understand the risks and benefits of your participation.

A clinical trial is medical research to study the safety and effectiveness of an investigational drug or device. The US Food and Drug Administration (FDA) uses information gathered in clinical trials to evaluate medications before approving them for use in the United States.

Before you are evaluated as a research participant, we will provide you with an approved Informed Consent Form (ICF) which you must read, understand, and sign before enrolling. The ICF outlines all procedures you will need to go through and all known risks and side effects of the investigational medication. Please read it carefully and ask all questions you might have.

Before conducting a clinical trial, pharmaceutical companies must obtain approval from the FDA to ensure that the investigational medication is appropriate to give to people. Additionally, all study procedures are reviewed by an independent Investigational Review Board (IRB) before they are allowed to be administered. All this is done to ensure that the study is ethical and that the risks are as low as possible. However, since the study participants are among the first to try the investigational medication, the risk of unanticipated side effects does exist. This is why the health of the people participating in the trials is continuously monitored and any serious side effects experienced by any of the people in the trial are promptly investigated.  If necessary, corrective actions, including termination of the trial, are taken.

Different studies have different enrollment requirements. Some studies are open only to healthy adults, other look for people with specific medical conditions, for instance, anxiety, depression, migraines, sexual dysfunction, etc. To determine whether you can enroll, we will ask several questions about your current health, your medical condition, and the medications you are taking. If you meet the study requirements, an appointment will be schedule for you to be evaluated in person.

Your participation in a research study is entirely voluntary, and you may withdraw from participation at any time and for any reason. During your screening visit and throughout the study, we will fully explain the risks and benefits of your study. If you change your mind, you may withdraw.

Any information you provide as a research participant is strictly confidential. It will not be sold and will be used only for the purposes of contacting you for relevant research studies.

Previous Research Studies Conducted

  • Clinical Performance Evaluation of a Point of Care Test to Detect Antibodies to SARS-CoV-2.
  • Phase 2, Double-blind, Randomized, Placebo-Controlled Study of NasoVAX in the Prevention of Clinical Worsening in Patients with Early Coronavirus Infectious Disease 2019 (COVID-19).
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies in Preventing SARS-CoV-2 Infection in Household Contacts of Individuals Infected with SARS CoV-2.
  • A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determined the Safety and Efficacy of AAZD7442 for the treatment of COVID-19 in Non-Hospitalized Adults (TACKLE).
  • A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY38119253 and LY3832479 in Participants with Mild to Moderate COVID-19 Illness.
  • A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-0472 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection.
  • A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2.
  • An Interventional, Efficacy, and Safety, Phase 2, Randomized, Double-Blind, 2-Arm Study to Investigate A Repeat 5-Day Course of Nermatrelvir/Ritonavir compared to Placebo/Ritonavir in participants at least 12 years of age with Rebound of COVID-19 Symptoms and Rapid Antigen Test Positivity.
  • A Study of Acute Respiratory Infections in Global Outpatient Setting (ARGOS).
  • A Phase 2b, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Dose Ranging Study to Evaluate Virological Response and Safety of Oral PF_07817883 in Non-Hospitalized Symptomatic Adult Participants with COVID-19.
  • A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer’s Disease.
  • A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, to Evaluate the Safety and Efficacy of SB-01 For Injections for the Treatment of Lumbar Degenerative Disc Disease.
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults with Obesity.
  • The Evaluation of a Nasal Compression Device in Comparison to Digital Nasal Compression for Stopping Epistaxis.
  • A Multi-Center, Prospective, Open-Label, Controlled Study of the Pharmacokinectics and Safety of the LicartTM Topical System in Pediatric and Adult Participants with Minor Soft Tissue Injuries.
  • A Prospective, Multi-Center, observational Study for Signal-C Test Evaluation (PROMISE).
  • POC SARS-CoV-2 Diagnostic PCR Device Comparison to FDA Approved Reference PCR Test.
  • Clinical Performance Evaluation of a Point of Care Test to Detect Antibodies to SARS-CoV-2.
  • POC SARS-CoV-2 Diagnostic PCR Device Comparison to FDA Approved Reference PCR Test.
  • A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy with Monoclonal Antibodies in Participants with Mild to Moderate COVID-19 Illness (BLAZE-4).
  • An Interventional Phase 2/3, Adaptive, Multi-center, Randomized, Double-Blind Study to Investigate Efficacy and Safety of Oral Sisunatovir Compared with Placebo in Non-Hospitalized Symptomatic Adults with Respiratory Syncytial Virus Infections Who Are at Risk of Progression to Severe Illness.
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Non-hospitalized Participants.
  • A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike(s) SRS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with COVID-19.
Our Research Partners

There's More to Explore at Next Level!

Subscribe to be notified when we publish blogs, videos, press releases and more!

Subscribe to our Podcast

Tune into Health Xplained for up to date insights from real health care professionals!

Explore Episodes

Contact the Research Team

GET THE MOBILE APP

For fast and easy scheduling, download or open the Next Level mobile app! Click the icon below to get started. 

Skip to content